PL2040753T3 - Inhibitory progastryny w leczeniu raka okrężnicy - Google Patents

Inhibitory progastryny w leczeniu raka okrężnicy

Info

Publication number
PL2040753T3
PL2040753T3 PL07734620T PL07734620T PL2040753T3 PL 2040753 T3 PL2040753 T3 PL 2040753T3 PL 07734620 T PL07734620 T PL 07734620T PL 07734620 T PL07734620 T PL 07734620T PL 2040753 T3 PL2040753 T3 PL 2040753T3
Authority
PL
Poland
Prior art keywords
progastrin
inhibitors
treatment
colon cancer
colon
Prior art date
Application number
PL07734620T
Other languages
English (en)
Inventor
Frédéric HOLLANDE
Dominique Joubert
Philippe Jay
Julie Pannequin
Nathalie Delaunay
Jean-François BOURGAUX
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Centre National De La Recherche Scientifique (Cnrs)
Université De Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique (Cnrs), Université De Montpellier filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of PL2040753T3 publication Critical patent/PL2040753T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL07734620T 2006-05-22 2007-05-21 Inhibitory progastryny w leczeniu raka okrężnicy PL2040753T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06290823 2006-05-22
EP07734620.3A EP2040753B8 (en) 2006-05-22 2007-05-21 Progastrin inhibitors in the treatment of colon cancer
PCT/IB2007/001312 WO2007135542A2 (en) 2006-05-22 2007-05-21 Progastrin inhibitors in the treatment of colon cancer

Publications (1)

Publication Number Publication Date
PL2040753T3 true PL2040753T3 (pl) 2019-09-30

Family

ID=36941924

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07734620T PL2040753T3 (pl) 2006-05-22 2007-05-21 Inhibitory progastryny w leczeniu raka okrężnicy

Country Status (9)

Country Link
US (1) US20100209426A1 (pl)
EP (1) EP2040753B8 (pl)
JP (1) JP5651331B2 (pl)
CN (1) CN101460196A (pl)
AU (1) AU2007252986B2 (pl)
CA (1) CA2652768A1 (pl)
ES (1) ES2727306T3 (pl)
PL (1) PL2040753T3 (pl)
WO (1) WO2007135542A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
EP3301446B1 (en) 2009-02-11 2020-04-15 Caris MPI, Inc. Molecular profiling of tumors
AU2010306119A1 (en) 2009-10-16 2012-05-03 Centre National De La Recherche Scientifique (Cnrs) Monoclonal antibodies to progastrin and their uses
US9487582B2 (en) 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
AU2011231978B2 (en) * 2010-03-24 2014-12-18 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer
CN103261224B (zh) 2010-07-26 2015-10-07 瑟维尔实验室 用于肝癌治疗的方法和组合物
US9410955B2 (en) 2011-06-01 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for predicting the risk of developing a colonic neoplasia
US10139415B2 (en) 2013-02-27 2018-11-27 Daiichi Sankyo Company, Limited Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
CN104225619B (zh) * 2013-06-09 2018-04-17 上海吉凯基因化学技术有限公司 人ilk基因治疗肿瘤的用途及其相关药物
WO2016066671A1 (en) * 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
CN110194787B (zh) * 2018-02-05 2022-05-17 中国医学科学院药物研究所 靶向抑制Wnt/β-catenin信号活性的多肽及其用途
EP3759492A1 (en) * 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
CN108982858B (zh) * 2018-07-05 2021-06-15 陕西师范大学 一种基于单克隆抗体检测人proGRP的双夹心ELISA试剂盒
CN115724949A (zh) * 2022-12-12 2023-03-03 郑州伊美诺生物技术有限公司 一种鼠源lgG单克隆抗体及其制备方法、应用
WO2026008533A1 (en) * 2024-07-01 2026-01-08 Janssen Pharmaceutica Nv Prmt5 inhibitors for treating adenomas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69827621T9 (de) * 1997-05-12 2007-06-06 Aphton Corp., Woodland Immunogene zusammensetzungen gegen den cck-b-gastrin-rezeptor und verfahren zur behandlung von tumoren
WO2004089976A1 (en) * 2003-04-08 2004-10-21 The University Of Melbourne Method of treatment
JP2008513536A (ja) * 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
US7854932B2 (en) * 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles

Also Published As

Publication number Publication date
EP2040753B8 (en) 2019-04-10
JP2009537627A (ja) 2009-10-29
EP2040753B1 (en) 2019-02-27
US20100209426A1 (en) 2010-08-19
CN101460196A (zh) 2009-06-17
WO2007135542A3 (en) 2008-05-15
CA2652768A1 (en) 2007-11-29
JP5651331B2 (ja) 2015-01-14
AU2007252986A1 (en) 2007-11-29
ES2727306T3 (es) 2019-10-15
AU2007252986B2 (en) 2013-03-21
WO2007135542A2 (en) 2007-11-29
EP2040753A2 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
PL2040753T3 (pl) Inhibitory progastryny w leczeniu raka okrężnicy
IL248204A0 (en) Combined treatment of tumors expressing 38cd
IL197315A0 (en) Treatment of cancer
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
GB0624874D0 (en) Treatment
GB0711342D0 (en) Well treatment
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
GB0600692D0 (en) Well treatment
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
EP2088862A4 (en) METHOD OF TREATING CANCER
IL206189A0 (en) Compound for use in the treatment of cancer
GB0716784D0 (en) Well treatment
GB0707556D0 (en) Treatment for cancer
GB0723100D0 (en) Treatment of HFnEF
GB0604460D0 (en) Treatment
GB0710871D0 (en) Cancer treatment
IL201318A0 (en) Use of hdac inhibitors for the treatment of gastrointestinal cancers
GB0600903D0 (en) Treatment of cancer
GB0622581D0 (en) Treatment of cancer
GB0602857D0 (en) The treatment of sialorrhoea
GB0618199D0 (en) Cancer treatment
GB0604741D0 (en) Cancer Treatment
GB0604114D0 (en) Combinations for the treatment of cancer